Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CellPress: Emerging Field of OV Based Cancer Immunotherapy

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Dec 07, 2022 10:45am

183 Views

Post# 35156176

RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

I'm puzzled. The 7am Central time, presentation should be done.
no news. Perhaps they are waiting for the 5pm abstract.
That would certainly be after market close.
The San Antonio symposium talks about information embargo. Not clear , what they mean by " after presentation".
regardless. We will know more by end of Tomorrow.
does anyone have access to the abstracts?

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record